Curi RMB Capital LLC Has $10.02 Million Stock Holdings in BioLife Solutions, Inc. $BLFS

Curi RMB Capital LLC grew its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 438,685 shares of the medical equipment provider’s stock after purchasing an additional 4,870 shares during the period. Curi RMB Capital LLC’s holdings in BioLife Solutions were worth $10,020,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BLFS. T. Rowe Price Investment Management Inc. acquired a new position in shares of BioLife Solutions in the 1st quarter valued at $30,789,000. Royal Bank of Canada boosted its position in shares of BioLife Solutions by 762.8% in the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock valued at $15,948,000 after purchasing an additional 617,320 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $11,113,000. Millennium Management LLC boosted its position in shares of BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after purchasing an additional 377,111 shares during the period. Finally, Invesco Ltd. boosted its position in shares of BioLife Solutions by 9.6% in the 1st quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider’s stock valued at $81,106,000 after purchasing an additional 311,585 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Stephens assumed coverage on BioLife Solutions in a report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 price target on the stock. Zacks Research upgraded BioLife Solutions to a “strong-buy” rating in a report on Monday, August 11th. Finally, Wall Street Zen downgraded BioLife Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $31.29.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $25.53, for a total value of $255,300.00. Following the transaction, the chief marketing officer owned 124,618 shares in the company, valued at $3,181,497.54. The trade was a 7.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the business’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total value of $23,800,000.00. Following the completion of the transaction, the insider owned 7,707,165 shares in the company, valued at $183,430,527. This trade represents a 11.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,019,020 shares of company stock worth $47,765,813 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $25.87 on Friday. The business’s 50-day moving average price is $23.00 and its two-hundred day moving average price is $23.33. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.55. The company has a market capitalization of $1.24 billion, a P/E ratio of -215.57 and a beta of 1.78.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million during the quarter, compared to analysts’ expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.